Aytu BioPharma, Inc (AYTU) stock
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.00 (0.00%)
Close on Nov 18, 2026Market cap $28.91MP/E –Yield –
Aytu BioPharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Aytu BioPharma's operating income for the twelve months ending Jun 30, 2026 was -$8.32M. For fiscal 2026 it was -$8.32M. The highest annual figure on record is -$52.41K in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$8.32M | – |
| FY2025 | Jun 30, 2025 | -$7.83M | – |
| FY2024 | Jun 30, 2024 | -$1.59M | – |
| FY2023 | Jun 30, 2023 | -$17.07M | – |
| FY2022 | Jun 30, 2022 | -$109.91M | – |
| FY2021 | Jun 30, 2021 | -$58.87M | – |
| FY2020 | Jun 30, 2020 | -$21.13M | – |
| FY2019 | Jun 30, 2019 | -$16.85M | – |
| FY2018 | Jun 30, 2018 | -$19.70M | – |
| FY2017 | Jun 30, 2017 | -$20.13M | – |
| FY2016 | Jun 30, 2016 | -$21.70M | – |
| FY2015 | Jun 30, 2015 | -$7.63M | – |
| FY2013 | Aug 31, 2013 | -$52.41K | – |
| FY2012 | Aug 31, 2012 | -$56.36K | – |
| FY2011 | Aug 31, 2011 | -$133.62K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$777.00K | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$4.06M | -267.9% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$1.97M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$1.50M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$7.62M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $2.42M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$1.70M | -153.9% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$930.00K | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$2.27M | -1445.0% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$1.60M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $3.15M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$867.00K | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $169.00K | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$8.56M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$6.87M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$1.81M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$16.94M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$53.42M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$11.29M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$27.70M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$24.07M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$25.67M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$5.58M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$3.56M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$6.63M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$4.79M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$4.97M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$4.74M | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$4.58M | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -$4.30M | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$4.55M | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -$3.42M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$3.83M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$7.52M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$3.99M | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$4.36M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$5.10M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$4.86M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$4.20M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$5.97M | – |
See a number that looks wrong?